Intrahepatic and perihilar cholangiocarcinoma, in particular, grew faster in young patients than in older patients. The report affirms research from other Western countries suggesting such a trend.

Zanidatamab-hrii received FDA accelerated approval for HER2-positive biliary tract cancer, showing a 52% objective response rate in the HERIZON-BTC-01 trial. Biliary tract cancers represent 3% of ...

For permission requests, please contact NEJM Reprints at [email protected] Incomplete stricture of the lower common bile duct was produced in 13 dogs by means of a technic similar to that of Imamoglu.

BRAF-Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape Precision medicine has become a dominant theme in the treatment of biliary tract cancers (BTCs). Although prognosis ...

Patients with biliary tract cancer have altered genetic architecture in some immune system receptors. This has been shown by researchers at Karolinska Institutet in Sweden in a new study published in ...

Biliary tract cancers are a diverse set of neoplasms arising from the biliary tract epithelium and include intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma, distal extrahepatic ...

An expert explains what biliary tract cancers are and the current landscape of treatment as well as future advancements. In the treatment of newly diagnosed biliary tract cancer, the current standard ...

THERE have been few fundamental contributions to the diagnosis and management of biliary-tract disease in recent years, but a current evaluation of the subject is justified in view of the large number ...

Credit: Jazz Pharmaceuticals Zanidatamab is a bispecific antibody that binds to 2 non-overlapping extracellular epitopes of the HER2 receptor. Findings showed the ORR was 52% (95% CI, 39-65), of which ...

CTX-009 is a bispecific antibody that simultaneously blocks Delta-like ligand 4 and vascular endothelial growth factor A. The Food and Drug Administration (FDA) has granted Fast Track designation to ...

The National Institute for Health and Care Excellence (NICE) has recommended durvalumab (IMFINZI, AstraZeneca) with gemcitabine and cisplatin as an option for treating locally advanced, unresectable, ...